DATABASE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

RNA — Atrium Therapeutics Inc.

RNA (Atrium Therapeutics Inc.) stock: $9.19, $157.1M market cap, $263.9M cash, -$106.8M EV, $159.4M fully diluted market cap. Next expected readout: May-28. Lead program: ATR 1072 (Cardiac Glycogenosis), Phase 1/2. Data from Fully Diluted's biotech stocks database.

Share price
$9.19
Market cap
$157.1M
Cash
$263.9M
Enterprise value
-$106.8M

Balance sheet

Cash$263.9M
Debt$0.0M
Net cash$263.9M
Enterprise value-$106.8M
Basic shares17.1M shares
Fully diluted shares17.3M shares
Fully diluted market cap$159.4M
Cash per share$15.43

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading RNA daily closes…

Loading price history…

Upcoming catalysts

ExpectedDrugPhaseIndicationMgmt guide
Jun 12 - Jul 24ATR 1072Phase 1/2Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.
Subscribe to Compounding Ego